

ERJ open research

Is asthma a risk factor for COVID-19? Are phenotypes important?

To the Editor:

Asthma is a major health problem all over the world [1]. Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory pathogen, it is important to quantify the risk that the current coronavirus disease 2019 (COVID-19) pandemic may represent for patients with asthma.

Relatively few data are available on the relationship between SARS-CoV-2 and patients with bronchial asthma. The first published studies from China suggested that asthma was not a risk factor for severe SARS-CoV-2 disease. Indeed, a study carried out in a cohort of 140 patients with COVID-19 found no infected asthma patients [2], and in a larger study of 1099 hospitalised patients, asthma was not identified as a risk factor [3]. Data from the Republic of Korea also indicate that asthma is not a relevant comorbidity [4]. However, the first study of critically ill patients in the United States found that five out of 24 patients with severe COVID-19 requiring intensive care unit admission were asthmatic [5], and a recent report for 393 patients admitted in a quaternary referral centre in New York establish a prevalence of asthma in this population of 12% [6].

In this climate of uncertainty, the aim of the study was to estimate the prevalence of asthma in patients hospitalised with severe pneumonia due to SARS-CoV-2, in a region where the prevalence of asthma is around 6% [7]. In the study, a cross-sectional analysis was performed for all patients admitted with SARS-CoV-2 infection confirmed by PCR to an asthma reference centre in a hospital serving a population of 500000 inhabitants, from 1 March to 30 June 2020. Age, sex, asthma status and the presence of comorbidities were recorded from the electronic medical records. In patients with asthma, data on the phenotype, severity and treatment received were also compiled. The severity of COVID-19 was recorded based on the needs of oxygen and ventilatory support and the chest radiograph findings. Disease was defined as severe if the patient needed inspiratory oxygen fraction (F_{IO_2}) <40%, very severe if they needed F_{IO_2} >40% and critical if they needed ventilatory support. The patients were divided into two groups: T2 (with the subgroups T2-Th2 and T2-ILC2) and Non-T2 (table 1). Patients were considered to have a T2-Th2 phenotype if, according to clinical history, they were allergic, a T2-ILC2 phenotype if they were not allergic and if an absolute eosinophil count of >300 cells·mm⁻³ was recorded in peripheral blood, and a non-T2 phenotype if the above criteria were not met. Patients with elevated IgE and a positive prick test or specific IgE to some of the usual pneumoallergens were considered to be allergic. The study was approved by the local Ethics Committee, and all subjects gave informed consent prior to participation (PR(AG)222/2020).

Up to June 30, 2020, 2226 patients with SARS-CoV-2 pneumonia were admitted to our centre. Of these, 71 (3.2%) were asthmatic according to clinical history (table 1), 42 (59%) of whom had the non-T2 phenotype, while 20 (28%) were allergic (T2-Th2) and nine (13%) eosinophilic (T2-ILC2). Nineteen patients (27%) had mild asthma, 29 (41%) moderate asthma and 23 (32%) severe asthma, according to the need for medication to achieve control of the disease. Eight patients (11%) were not receiving any regular treatment; 52 (73%) patients were taking inhaled corticosteroids (six as monotherapy). No correlation was observed between the dose of inhaled corticosteroids and COVID-19 severity. Chest radiograph indicated multilobar pneumonia in 45 (63%) patients, unilobar in 14 (20%) and diffuse interstitial involvement in nine (13%). Eighteen patients (25%) did not require oxygen therapy during admission. In 39 (55%)

@ERSpublications

These results reaffirm the idea that asthma does not appear to be a risk factor for the development of #COVID19. However, most of the asthma patients in this study had a non-T2 phenotype. https://bit.ly/38hIp18

Cite this article as: Muñoz X, Pilia F, Ojanguren I, *et al.* Is asthma a risk factor for COVID-19? Are phenotypes important? *ERJ Open Res* 2021; 7: 00216-2020 [https://doi.org/10.1183/23120541.00216-2020].

Copyright ©ERS 2021. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.





TABLE 1 Characteristics of asthmatic patients admitted since the onset of the coronavirus disease 2019 (COVID-19) pandemic until 30 June 2020

T2 Non-T2 Subjects n 29 42 Age years 56 (15-85) 63 (28-93) 0.258 Male sex 9 (31) 18 (43) 0.313 Smoking habit 0 0.691 32 (76) 0.790 Ex-smoker 20 (69) 32 (76) 0.790 Ex-smoker 7 (24) 8 (19) 0.839 Comorbidities 6 (21) 11 (26) 44 0.439 0.431 0.431 Observer 2 (77) 2 (51) 0.431 0.431 0.431 0.431 Observer 2 (77) 2 (51) 0.431 0.432 0.990 0.441 0.431 0.431 0.431 0.431 0.431 0.431 0.4		Asthma phenotype		p-value
Age years 56 [15-85] 63 [28-93] 0.258 Male sex 9 [31] 18 [43] 0.313 Smoking habit		T2	Non-T2	
Male sex 9 (31) 18 (43) 0.313 Smoking habit	Subjects n	29	42	
Smoking habit Simoker 2 (7) 2 (5) Nonsmoker 20 (69) 32 (76) 0.790 Ex-smoker 7 (24) 8 (19) 0 BMI kg·m ⁻² 30 (15-38) 29 (16-43) 0.839 Comorbidities 6 (21) 11 (26) 1 AHT 15 (52) 20 (48) 0 Cardiomyopathy 6 (21) 10 (24) 0.839 Obesity 10 (34) 13 (31) 0.632 Nephropathy 1 (3) 5 (12) 0 Cancer 2 (7) 2 (5) 0 0 Other pneunopathy 3 (10) 4 (9) 0 0 0 Other pneumopathy 3 (10) 4 (9) 0 0 0 0 Severe persistent 10 (34) 13 (31) 0 0 0 0 0 Mid persistent 10 (34) 13 (31) 0 0 0 0 0 0 0 0 0 0 0 13 (31) </td <td>Age years</td> <td>56 (15–85)</td> <td>63 (28–93)</td> <td>0.258</td>	Age years	56 (15–85)	63 (28–93)	0.258
Smoker 2 (7) 2 (5) Nonsmoker 20 (69) 32 (75) 0.790 Ex-smoker 7 (24) 8 (19) 0.839 Comorbidities 30 (15-38) 29 (16-43) 0.839 Comorbidities 6 (21) 11 (26) AHT AHT 15 (52) 20 (48) 20 (50) Cardiomyopathy 6 (21) 10 (24) 0.632 Obesity 10 (34) 13 (31) 0.632 Ne comorbidities 6 (21) 10 (24) 0.632 Obesity 10 (34) 13 (31) 0.632 Cancer 2 (7) 2 (5) 0 0 Other pneumopathy 3 (10) 4 (9) 0 0.001 Astma severity 20 (69) 0 0.0001 0.0001 Ige Levels KU- ¹⁻¹ 160 (10-1299) 36 (10-269) 0.001 Ige Levels KU- ¹⁻¹ 160 (10-1299) 36 (10-269) 0.001 Ige Levels KU- ¹⁻¹ 160 (10-1299) 36 (10-269) 0.001 Ige Levels KU- ¹⁻¹ <td>Male sex</td> <td>9 (31)</td> <td>18 (43)</td> <td>0.313</td>	Male sex	9 (31)	18 (43)	0.313
Nonsmoker 20 (69) 32 (76) 0.790 Ex-smoker 7 (24) 8 (19) 7 BMI kg·m²² 30 (15-38) 29 (16-43) 0.839 Comorbidities 6 (21) 11 (26) 7 AHT 15 (52) 20 (48) 20 (48) Cardiomyopathy 6 (21) 13 (31) 0.632 Desity 10 (34) 13 (31) 0.632 Nephropathy 1 (3) 5 (12) 20 (48) Cancer 2 (7) 2 (5) 0 Other pneumopathy 3 (10) 4 (9) 0 Other 7 (24) 7 (17) 7 Atopy 20 (69) 0 0.0001 Astima severity 10 (34) 13 (31) 0 Moderate persistent 11 (38) 18 (43) 0.990 Severe persistent 10 (34) 13 (31) 0 IgE levels kU-1 ⁻¹ 160 (10-269) 0.001 12 Astima security 1 13 (10) 0 12	Smoking habit			
Ex-smoker 7 (24) 8 (19) BM kg·m ⁻² 30 (15–38) 29 (16–43) 0.839 Comorbidities 11 (26) AH 15 (52) 20 (48) Cardionyopathy 6 [21] 13 (31) 0.632 Diabetes 6 (21) 10 (24) 0 Obesity 10 (34) 13 (31) 0.632 Nephropathy 1 (3) 5 (12) 0 Cancer 2 (7) 2 (5) 0 Other 7 (24) 7 (17) 0 Atopy 20 (69) 0 0.0001 Astma severity 11 (38) 18 (43) 0.990 Severe persistent 10 (34) 13 (31) 0 Blod eosinophils per mm ³ 300 (0-1400) 100 (0-200) 0.0001 FFV, % predicted 81 (58-133) 72 (35-112) 0.129 Astma medication 11 (3) 5 (12) 0.129 Astma medication 1 12 12 No treatment 3 (10) 5 (12) 0.807 (20-160)	Smoker	2 (7)	2 (5)	
BMI kg·m ⁻² 30 (15-38) 29 (16-43) 0.839 Comorbidities	Nonsmoker			0.790
Comorbidities 6 [21] 11 [26] AHT 15 [52] 20 [48] Cardiomyopathy 6 [21] 13 [31] Diabetes 6 [21] 13 [31] Diabetes 6 [21] 13 [31] Desity 10 [34] 13 [31] 0.632 Nephropathy 1 [3] 5 [12] Cancer 2 [7] 2 [5] Other pneumopathy 3 [10] 4 [9] 0 0.0001 Astma severity 7 [124] 7 [17] Atopy 20 [69] 0 0.0001 Astma severity 8 [28] 11 [26] Moderate persistent 11 [38] 18 [43] 0.990 Severe persistent 10 [34] 13 [31] 0 0.0001 Blood eosinophils per mm ³ 300 [0-1400] 100 [0-200] 0.0001 FEV, % predicted 81 [58-133] 72 [35-112] 0.129 Astma medication 1 13 5 12] IC + LABA 17 [59] 29 [69] 0.807 Oral corticosteroids 0 </td <td></td> <td>· · ·</td> <td>8 (19)</td> <td></td>		· · ·	8 (19)	
No comorbidities 6 (21) 11 (26) AHT 15 (52) 20 (48) Cardiomyopathy 6 (21) 13 (31) Diabetes 6 (21) 10 (24) Obesity 10 (34) 13 (31) 0.632 Nephropathy 1 (3) 5 (12) 0 Cancer 2 (7) 2 (5) 0 Other pneumopathy 3 (10) 4 (9) 0 Other preumopathy 3 (10) 4 (9) 0 Other preumopathy 3 (10) 4 (9) 0 Other preumopathy 3 (10) 4 (9) 0 Atopy 20 (69) 0 0.0001 Asthma severity 11 (38) 18 (43) 0.990 Severe persistent 10 (34) 13 (31) 0 Blood eosinophils per mm ³ 300 (0-1400) 100 (0-200) 0.0001 IFEV, % predicted 81 (58-133) 72 (35-112) 0.129 Astma medication 3 (10) 5 (12) 5 (12) No treatment 3 (10) <td< td=""><td></td><td>30 (15–38)</td><td>29 (16–43)</td><td>0.839</td></td<>		30 (15–38)	29 (16–43)	0.839
AHT 15 [52] 20 (48) Cardiomyopathy 6 [21] 13 [31] Diabetes 6 [21] 10 [24] Obesity 10 [34] 13 [31] 0.632 Nephropathy 1 [3] 5 [12] cancer Cancer 2 [7] 2 [5] 0 Other pneumopathy 3 [10] 4 [9] 0 Other 7 [24] 7 [17] 7 Atopy 20 [69] 0 0.0001 Astima severity 11 [38] 18 [43] 0.990 Severe persistent 10 [34] 13 [31] 0 Blood eosinphils per mm ³ 300 [0-14:00] 100 [0-2:00] 0.0001 IgE levels kU-L ⁻¹ 160 (10-12:99) 36 (10-2:69) 0.001 FFV, % predicted 81 [58-133] 72 [35-112] 0.129 Astima medication 1 1 1 1 No treatment 3 [10] 5 [12] 5 1 Gradictionseroids 0 1 [2] 1 1 3 <td></td> <td></td> <td></td> <td></td>				
Cardiomyopathy 6 [21] 13 [31] Diabetes 6 [21] 10 [24] Obesity 10 [34] 13 [31] Diabetes 6 [21] 10 [24] Obesity 10 [34] 13 [31] Nephropathy 1 [3] 5 [12] Cancer 2 [7] 2 [5] Other pneumopathy 3 [10] 4 [9] Other Preumopathy 3 [10] 4 [9] Other 7 [124] 7 [17] Atopy 20 [69] 0 0.0001 Astma severity " " " Mild persistent 11 [38] 18 [43] 0.990 Severe persistent 10 [34] 13 [31] " Blood eosinophils per mm ³ 300 [0-1400] 100 [0-269] 0.001 IgE levels kU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.001 IgE levels kU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.001 IgE levels kU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.0129 Astma medication 3 [10]				
Diabetes 6 (21) 10 (24) Obesity 10 (34) 13 (31) 0.632 Nephropathy 1 (3) 5 (12) Cancer 2 (7) 2 (5) Other pneumopathy 3 (10) 4 (9) Other 7 (24) 7 (17) Atopy 20 (69) 0 0.0001 Astima severity	AHT	15 (52)	20 (48)	
Obesity 10 (34) 13 (31) 0.632 Nephropathy 1 (3) 5 (12) Cancer 2 (7) 2 (5) Other pneumopathy 3 (10) 4 (9) Other 7 (24) 7 (17) Atopy 20 (69) 0 0.0001 Asthma severity				
Nephropathy 1 [3] 5 [12] Cancer 2 [7] 2 [5] Other pneumopathy 3 [10] 4 [9] Other 7 [24] 7 [17] Atopy 20 [69] 0 0.0001 Asthma severity 11 [38] 18 [43] 0.990 Severe persistent 10 [34] 13 [31] 0 Blood eosinophils per mm ³ 300 [0-1400] 100 [0-200] 0.0001 IgE levels KU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.001 IgE levels KU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.001 IgE levels KU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.001 FEV, % predicted 81 [58-133] 72 [35-112] 0.129 Asthma medication 1 1 1 1 1 No treatment 3 [10] 5 [12] 1 <td></td> <td></td> <td></td> <td></td>				
Cancer 2 (7) 2 (5) Other pneumopathy 3 (10) 4 (9) Other 7 (24) 7 (17) Atopy 20 (69) 0 0.0001 Astima severity 0 0 0.0001 Astima severity 8 (28) 11 (26) 0 0.0001 Mild persistent 11 (38) 18 (43) 0.990 0.0001 Severe persistent 10 (34) 13 (31) 0 0 0.0001 Blood cosinophils per mm ³ 300 (0-1400) 100 (0-200) 0.0001 IgE levels kU-L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 FEV, % predicted 81 (58-133) 72 (35-112) 0.129 Asthma medication 0 1 (2) 0 0 No treatment 3 (10) 5 (12) 5 (12) 5 (12) SABA 5 (17) 1 (2) 0 0 IC 1 (3) 0 0 0 Antileukotrienes 3 (10) 0 0 0				0.632
Other 3 [10] 4 [9] Other 7 [24] 7 [17] Atopy 20 [69] 0 0.0001 Asthma severity				
Other 7 [24] 7 [17] Atopy 20 [69] 0 0.0001 Asthma severity 0 0.0001 Mild persistent 8 [28] 11 [26] 0 Moderate persistent 11 [38] 18 [43] 0.990 Severe persistent 10 [34] 13 [31] 0 Blood cosinophils per mm ³ 300 [0-1400] 100 [0-200] 0.0001 IgE levels KU-L ⁻¹ 160 [10-1299] 36 [10-269] 0.001 FEV, % predicted 81 [58-133] 72 [35-112] 0.129 Asthma medication 0 5 [12] 0.129 No treatment 3 [10] 5 [12] 0.129 SABA 5 [17] 1 [2] 0.121 IC + LABA 17 [59] 29 [69] 0.875 Antiheukotrienes 3 [10] 0 4 [9] 0.875 Antihistamines 3 [10] 0 0 0 O 0 0 0 0 Others 0 0 0 <				
Atopy 20 (69) 0 0.0001 Asthma severity	Other pneumopathy			
Asthma severity Nild persistent 8 [28] 11 [26] Moderate persistent 11 [38] 18 [43] 0.900 Severe persistent 10 [34] 13 [31] 1000 [0-200] 0.0001 Blood eosinophils per mm ³ 300 [0-1400] 100 [0-200] 0.0001 IgE levels kU-L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 FEV, % predicted 81 (58-133) 72 (35-112) 0.129 Asthma medication 0 5 [17] 1 [2] 0.129 Asthma medication 0 1 [2] 0.129 No treatment 3 [10] 5 [12] 0.875 Antileukotrienes 3 [10] 0 0 Antileukotrienes 3 [10] 0 0 Anti-IgE 1 [3] 0 0 Anti-IgE 1 [3] 0 0 Anti-IgE 1 [3] 0 0 Anti-IgE 0 0 0 0 Others 0 0 0 0 CoVID-19 sev				
Mild persistent 8 (28) 11 (26) Moderate persistent 11 (38) 18 (43) 0.990 Severe persistent 10 (34) 13 (31) 0.0001 Blood eosinophils per mm ³ 300 (0-1400) 100 (0-200) 0.0001 IgE levels kU-L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 IgE levels kU-L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 FEV, % predicted 81 (58-133) 72 (35-112) 0.129 Asthma medication 1 (3) 5 (12) 0.129 No treatment 3 (10) 5 (12) 0.129 Grad corticosteroids 0 1 (2) 0.875 Antileukotrienes 3 (10) 4 (9) 0.875 Antileukotrienes 3 (10) 0 0 Anti-L-5 0 0 0 0 Others 0 0 0.961 0.961 COVID-19 severity 13 (45) 5 (12) 0.961 Mild 13 (45) 5 (12) 0.961 Severe		20 (69)	0	0.0001
Moderate persistent 11 (38) 18 (43) 0.990 Severe persistent 10 (34) 13 (31) 00 Blood eosinophils per mm ³ 300 (0-1400) 100 (0-200) 0.0001 IgE levels kU-L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 FEV, % predicted 81 (58-133) 72 (35-112) 0.129 Asthma medication 3 (10) 5 (12) 5 (12) SABA 5 (17) 1 (2) 1 IC 1 (3) 5 (12) 0.875 Antileukotrienes 3 (10) 4 (9) 0.875 Antileukotrienes 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 O 0 0 0 0.961 COVID-19 severity 0 3 (7) 0.961 Mild 13 (45) 5 (12) 0.961 Very severe 1 (3) 3 (7) 0.18 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Severe persistent10 (34)13 (31)Blood eosinophils per mm³300 (0-1400)100 (0-200)0.0001IgE levels kU·L ⁻¹ 160 (10-1299)36 (10-269)0.001FEV, % predicted81 (58-133)72 (35-112)0.129Astima medication 72 (35-112)0.129No treatment3 (10)5 (12)SABA5 (17)1 (2)IC1 (3)5 (12)Oral corticosteroids01 (2)Oral corticosteroids01 (2)Antiheukotrienes3 (10)0Anti-IgE1 (3)0Anti-IgE1 (3)0Others00IC µg per 24 h800 (320-1600)800 (200-1600)OVID-19 severityMild13 (45)5 (12)Severe1 (3)3 (7)Critical5 (17)5 (12)Radiology patternWithout alteration1 (3)2 (5)Without alteration1 (3)2 (5)Unilobar pneumonia7 (24)7 (17)0.854	1			
Blood eosinophils per mm ³ 300 (0-1400) 100 (0-200) 0.0001 IgE levels kU·L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 FEV ₁ % predicted 81 (58-133) 72 (35-112) 0.129 Asthma medication 0 0.121 No treatment 3 (10) 5 (12) 0.129 JC 1 (3) 5 (12) 0.121 IC 1 (3) 5 (12) 0.121 Oral corticosteroids 0 1 (2) 0.875 Antileukotrienes 3 (10) 4 (9) 0.875 Antileukotrienes 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 IC µg per 24 h 800 (320-1600) 800 (200-1600) 0.961 COVID-19 severity 13 (45) 5 (12) Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) 7 (12) Critical 5 (17) 5 (12) 7 (12) <td></td> <td></td> <td></td> <td>0.990</td>				0.990
IgE levels kU·L ⁻¹ 160 (10-1299) 36 (10-269) 0.001 FEV ₁ % predicted 81 (58-133) 72 (35-112) 0.129 Asthma medication			13 (31)	
FEV₁ % predicted 81 (58–133) 72 (35–112) 0.129 Asthma medication 0 5 (12) 0 No treatment 3 (10) 5 (12) 5 SABA 5 (17) 1 (2) 1 IC 1 (3) 5 (12) 1 IC 1 (3) 5 (12) 1 IC+LABA 17 (59) 29 (69) 0 Oral corticosteroids 0 1 (2) 1 Antileukotrienes 3 (10) 4 (9) 0.875 Antihistamines 3 (10) 0 0 0 Anti-IgE 1 (3) 0 0 0 Anti-IgE 1 (3) 0 0 0 Others 0 0 0 0 IC µg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity Nild 13 (45) 5 (12) 5 Severe 10 (35) 29 (69) 0.018 0 Very severe 1 (3) 3 (7)	Blood eosinophils per mm ³			
Asthma medication No treatment 3 (10) 5 (12) SABA 5 (17) 1 (2) IC 1 (3) 5 (12) IC+LABA 17 (59) 29 (69) Oral corticosteroids 0 1 (2) Antileukotrienes 3 (10) 4 (9) 0.875 Antileukotrienes 3 (10) 0 4 Anti-IgE 1 (3) 0 4 Anti-IgE 1 (3) 0 0 Others 0 0 0 Others 0 0 0 IC µg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity 13 (45) 5 (12) Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) 17 Critical 5 (17) <t< td=""><td></td><td></td><td></td><td></td></t<>				
No treatment 3 (10) 5 (12) SABA 5 (17) 1 (2) IC 1 (3) 5 (12) IC+LABA 17 (59) 29 (69) Oral corticosteroids 0 1 (2) Antileukotrienes 3 (10) 4 (9) 0.875 Antileukotrienes 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 Anti-IL-5 0 0 0 Others 0 0 0 IC µg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity Mild 13 (45) 5 (12) Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) 5 (12) Severe 1 (3) 3 (7) 5 (12) Radiology pattern 5 (17) 5 (12) 5 (12) Without alteration 1 (3) 2 (5) 10 (13) Unilobar pneumonia 7 (24) </td <td></td> <td>81 (58–133)</td> <td>72 (35–112)</td> <td>0.129</td>		81 (58–133)	72 (35–112)	0.129
SABA 5 (17) 1 (2) IC 1 (3) 5 (12) IC+LABA 17 (59) 29 (69) Oral corticosteroids 0 1 (2) Antileukotrienes 3 (10) 4 (9) 0.875 Antileukotrienes 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 Anti-IL-5 0 0 0 Others 0 0 0 IC µg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity 10 (35) 5 (12) 0 Mild 13 (45) 5 (12) 0 Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) 0 Critical 5 (17) 5 (12) 0 Radiology pattern 1 (3) 3 (7) 0 Without alteration 1 (3) 2 (5) 0 Unilobar pneumonia 7 (24) 7 (17) 0.854			- 4 - 1	
$\begin{array}{c c c c c c c } IC & 1 (3) & 5 (12) \\ IC+LABA & 17 (59) & 29 (69) \\ Oral corticosteroids & 0 & 1 (2) \\ Antileukotrienes & 3 (10) & 4 (9) & 0.875 \\ Antihistamines & 3 (10) & 0 \\ Anti-IgE & 1 (3) & 0 \\ Anti-IgE & 1 (3) & 0 \\ Anti-IL-5 & 0 & 0 \\ Others & 0 & 0 \\ IC \ \mug \ per 24 \ h & 800 (320-1600) & 800 (200-1600) & 0.961 \\ \hline {COVID-19 \ severity} & & & & \\ Mild & 13 (45) & 5 (12) \\ Severe & 10 (35) & 29 (69) & 0.018 \\ Very \ severe & 1 (3) & 3 (7) \\ Critical & 5 (17) & 5 (12) \\ \hline {Radiology \ pattern} & & & \\ Without \ alteration & 1 (3) & 2 (5) \\ Unilobar \ pneumonia & 7 (24) & 7 (17) & 0.854 \\ \end{array}$				
IC+LABA 17 (59) 29 (69) Oral corticosteroids 0 1 (2) Antileukotrienes 3 (10) 4 (9) 0.875 Antihistamines 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 Anti-IL-5 0 0 0 Others 0 0 0 IC μg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity 0 0 Mild 13 (45) 5 (12) 0 Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) Critical 5 (17) 5 (12) Radiology pattern 5 (17) 5 (12) Without alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854				
Oral corticosteroids 0 1 [2] Antileukotrienes 3 (10) 4 (9) 0.875 Antihistamines 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 0 0 0 Anti-IL-5 0 0 0 Others 0 0 0 IC µg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity 800 (320–1600) 800 (200–1600) 0.961 Mild 13 (45) 5 (12) 0 Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) 0.018 Very severe 1 (3) 3 (7) 5 (12) Radiology pattern 5 (17) 5 (12) 5 (12) Without alteration 1 (3) 2 (5) 0.054				
Antileukotrienes 3 (10) 4 (9) 0.875 Antihistamines 3 (10) 0 0 Anti-IgE 1 (3) 0 0 Anti-IgE 1 (3) 0 0 Anti-IL-5 0 0 0 Others 0 0 0 IC μg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity 0 0 Mild 13 (45) 5 (12) 0.018 Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7)				
$\begin{array}{c c c c c c c } & 3 (10) & 0 & & & \\ Anti-IgE & 1 (3) & 0 & & \\ Anti-IL-5 & 0 & 0 & & \\ 0 & 0 & 0 & & \\ 0 & 0 & 0$				
Anti-IgE 1 (3) 0 Anti-IL-5 0 0 Others 0 0 IC μg per 24 h 800 (320–1600) 800 (200–1600) 0.961 COVID-19 severity 800 (320–1600) 800 (200–1600) 0.961 Severe 10 (35) 5 (12) 0 0 Very severe 1 (3) 3 (7) 0.018 Very severe 1 (3) 3 (7) 5 (12) Radiology pattern 5 (17) 5 (12) 5 (12) Without alteration 1 (3) 2 (5) 0.018 Unilobar pneumonia 7 (24) 7 (17) 0.854				0.875
Anti-IL-5 0 0 Others 0 0 IC μg per 24 h 800 (320-1600) 800 (200-1600) 0.961 COVID-19 severity Mild 13 (45) 5 (12) Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) Critical 5 (17) 5 (12) Radiology pattern 5 (17) 5 (12) Without alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854				
Others 0 0 IC μg per 24 h 800 (320-1600) 800 (200-1600) 0.961 COVID-19 severity				
IC μg per 24 h 800 (320-1600) 800 (200-1600) 0.961 COVID-19 severity				
COVID-19 severity Mild 13 (45) 5 (12) Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) Critical 5 (17) 5 (12) Radiology pattern Unitobar pneumonia 1 (3) 2 (5) Unitobar pneumonia 7 (24) 7 (17) 0.854			-	
Mild 13 (45) 5 (12) Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) Critical 5 (17) 5 (12) Radiology pattern 5 (17) 5 (12) Without alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854		800 (320–1600)	800 (200–1600)	0.961
Severe 10 (35) 29 (69) 0.018 Very severe 1 (3) 3 (7) 7 Critical 5 (17) 5 (12) 7 Radiology pattern Vithout alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854	-		5 (4.0)	
Very severe 1 (3) 3 (7) Critical 5 (17) 5 (12) Radiology pattern Vithout alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854				
Critical 5 (17) 5 (12) Radiology pattern 7 (24) 7 (17) 0.854				0.018
Radiology pattern 2 (5) Without alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854				
Without alteration 1 (3) 2 (5) Unilobar pneumonia 7 (24) 7 (17) 0.854		5 (17)	5 (12)	
Unilobar pneumonia 7 (24) 7 (17) 0.854		1 (0)	0 (5)	
				0.05 (
Multilopar pneumonia 18 162 27 1641	•			0.854
Diffuse interstitial disease 3 (11) 6 (14)				0.7/0
Follow-up, death 2 (7) 2 (5) 0.762	rollow-up, death	2 (/)	2 [5]	0.762

Data are presented as median (range) or n (%), unless otherwise stated. Comparison of the demographic and clinical variables was performed using the Fisher exact test for qualitative variables and Mann-Whitney U-test for continuous variables. Spearman's rank correlation test was applied to determine correlations between the various parameters studied. COVID-19 severity: severe, inspiratory oxygen fraction (F_{IO_2}) <40%; very severe, F_{IO_2} >40%; critical, need for ventilatory support. Dose of corticosteroids expressed as budesonide equivalent. T2: type 2; BMI: body mass index; AHT: arterial hypertension; FEV₁: forced expiratory volume in 1 s; SABA: short-acting β_2 -agonist; IC: inhaled corticosteroid; LABA: long-acting β_2 -agonist; IL: interleukin. Bold indicates statistical significance. patients, the level of F_{IO_2} required was below 40%, and 14 (20%) patients presented with a very severe or critical infection (10 were admitted to the intensive care unit). In patients with a non-T2 phenotype, a greater severity of COVID-19 disease is observed (p=0.018). In 17 (24%) patients, asthma was the sole chronic disease (11 presented with a non-T2 and six a T2-Th2 phenotype). In the 54 (76%) patients who presented with a comorbidity, the most frequent was hypertension in 35 patients, followed by obesity (body mass index >30) (n=23), cardiomyopathy (n=19) and diabetes (n=16). In the group of patients without comorbidity, asthma was mild in seven patients, moderate in six and severe in four patients. Evolution was satisfactory in all 17 patients. In fact, in the total population, the evolution with standard treatment was good in 67 (94%) patients, while four died.

Our results support the idea that asthma does not appear to be a risk factor for the development of COVID-19, at least in hospitalised patients with more serious forms of infection. The question arises as to whether it might even be a protective factor. In the present study we found that only 3.2% of hospitalised patients with severe disease had asthma – a prevalence lower than that in the general population in our setting, which is around 6% [6]. It should also be borne in mind that 54 (76%) of the 71 affected patients had comorbidities that have been shown to be directly related to the involvement of SARS-CoV-2 [8]. The prevalence of patients with asthma without other comorbidities suffering from severe disease falls to only 0.8%, a rate similar to the 0.9% reported by Li *et al.* [8] in Wuhan, where the prevalence of asthma is also 6%.

The explanation for this finding is not clear. Some authors have suggested that inhaled corticosteroid treatment may protect these patients from the disease or may reduce the severity [9]. In favour of this hypothesis is the *in vitro* finding that inhaled corticosteroids alone or in combination with bronchodilators can suppress the replication of the coronavirus and decrease the production of cytokines [10]. However, it is striking that in the present study we did not find a relationship between the dose of inhaled corticosteroids and the severity of COVID-19.

The T2 response is basically characterised by eosinophilic inflammation [7]. The presence of activated eosinophils may protect individuals from infection by this virus, in a similar way to that already described for other viruses [11], although a relationship between the level of eosinophils and the possible protection against the virus has not been found in the present study. Another possible explanation is the interrelation between asthma and the renin-angiotensin system. Activation of the ACE2 receptor, the gateway for the virus into cells, regulates the asthmatic response in a rat asthma model [12]. One might speculate that the reduced activity of this receptor that favours the development of asthma might also prevent expression of the virus. In this sense, it has been documented that patients with atopic asthma have decreased expression of ACE2 receptors [13], and this process may be mediated by interleukin (IL)-13 [14]. In fact, in the present study, we have observed less severe COVID-19 in patients with the T2 phenotype. It may seem counter-intuitive that although excessive T2 inflammation is known to facilitate viral exacerbations of asthma [15], in these patients it is a protective element, and the presence of a cellular environment in which there is a T2 response with an increased presence of cytokines in the Th2 pathway may protect against SARS-CoV-2 infection. Therefore, the results of the present study suggest that SARS-CoV-2, like severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) but unlike other coronaviruses [16], has not been found to exacerbate asthma.

Although the present study has inherent limitations due to its design, the results suggest that asthma could be a protective factor against infection by the SARS-CoV-2 virus, especially in asthmatic patients with a T2 phenotype. Reproduction of these results in studies with larger numbers of patients could open up a new avenue of research in the fight against SARS-CoV-2.

Xavier Muñoz^{1,2,3}, Florencia Pilia¹, Iñigo Ojanguren ⁽²⁾^{1,2}, Christian Romero-Mesones¹ and María-Jesús Cruz^{1,2}

¹Servei de Pneumologia Hospital Vall d'Hebron, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. ²CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. ³Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autònoma de Barcelona, Barcelona, Spain.

Correspondence: Xavier Muñoz, Servei de Pneumologia, Hospital General Vall d'Hebron, Passeig Vall d'Hebron, 119, 08035 Barcelona, Spain. E-mail: xmunoz@vhebron.net

Received: 25 April 2020 | Accepted after revision: 27 Oct 2020

Conflict of interest: X. Muñoz reports personal fees from AstraZeneca and Boehringer Ingelheim, grants and personal fees from GlaxoSmithkline, grants from Menarini, personal fees from Novartis, personal fees from Teva and Mundifarma, grants and personal fees from Chiesi, and personal fees from Faes, outside the submitted work. F. Pilia has

nothing to disclose. I. Ojanguren reports personal fees from GSK, AstraZeneca, Novatis, Boehringer Ingelheim, Bial, MSD, Esteve and Chiesi, grants and personal fees from Mundipharma, and personal fees from TEVA, outside the submitted work. C. Romero-Mesones has nothing to disclose. M-J. Cruz has nothing to disclose.

References

- 1 Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Asthma Management and Prevention 2019. https://ginasthma.org. Date last accessed: 21 April 2020. Date last updated: 20 December 2020.
- 2 Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75: 1730–1741.
- 3 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.
- 4 Korean Society of Infectious Diseases, Korean Society of Pediatric Infectious Diseases, Korean Society of Epidemiology, Korean Society for Antimicrobial Therapy, Korean Society for Healthcare-associated Infection Control and Prevention, Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-10) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci 2020; 35: e112.
- 5 Bhatraju PK, Ghassemieh BJ, Nichols MN, *et al.* Covid-19 in critically ill patients in the Seattle region: case series. *N Engl J Med* 2020; 382: 2012–2022.
- 6 Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 382: 2372–2374.
- 7 GEMA 5.0. www.gemasma.com. Date last accessed: 21 April 2020.
- 8 Li X, Xu S, Yu M, *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146: 110–118.
- 9 Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020; 8: 436–438.
- 10 Yamaya M, Nishimura H, Deng X, *et al.* Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. *Respir Investig* 2020; 58: 155–168.
- 11 Percopo CM, Dyer KD, Ochkur SI, et al. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood 2014; 123: 1578–1586.
- 12 Dhawale VS, Amara VR, Karpe PA, *et al.* Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model. *Toxicol Appl Pharmacol* 2016; 306: 17–26.
- 13 Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020; 146: 203–206.
- 14 Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 2020; 146: 80–88.
- 15 Farne HA, Johnston SL. Immune mechanisms of respiratory viral infections in asthma. *Curr Opin Immunol* 2017; 48: 31–33.
- 16 Zheng XY, Xu YJ, Guan WJ, et al. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol 2018; 163: 845–853.